Form 4: Acrivon Therapeutics Chief Accounting Officer Reports Stock Transaction
SEC Form 4 Filing
Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, reports the withholding of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On August 14, 2024, Katharine Peterson, the Chief Accounting Officer of Acrivon Therapeutics, Inc., had 99 shares of common stock withheld by the issuer to satisfy tax obligations.
- The shares were withheld at a price of $7.02 per share.
- Following the transaction, Peterson directly owns 4,634 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a routine transaction related to tax obligations, so it has a neutral sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC when corporate insiders, like officers and directors, trade their company's stock. This filing indicates a routine transaction related to tax obligations upon vesting of restricted stock units, which is a common form of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 08/14/2024 | Date of stock transaction (tax withholding) |
| 08/16/2024 | Date of signature for the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.